Alexion and Zealand Pharma announce collaboration to develop peptide therapies
Alexion and Zealand Pharma announced a collaboration to discover and develop novel peptide therapies for complement-mediated diseases. The agreement provides Alexion with exclusive worldwide licenses, with and commercial rights, for up to four targets within the complement pathway. March 20, 2019